文献速递淋巴瘤

一种新型患者来源三维模型重现套细胞淋巴瘤淋巴结信号、免疫特征及体内依鲁替尼反应

A novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses.
PubMed 文献 · Leukemia · 2023-04-08

研究构建了首个人源套细胞淋巴瘤球状体(MCL-PDLS),由肿瘤B细胞、单核细胞和自体T细胞自组织成盘状结构,可重现MCL淋巴结增殖、NF-kB和BCR通路及T细胞耗竭特征。该模型重现体内依鲁替尼反应,并显示依鲁替尼联合纳武利尤单抗可能通过增强干扰素γ和颗粒酶B释放对依鲁替尼耐药病例有效。

要点

  • MCL-PDLS重现MCL淋巴结的增殖、NF-kB和BCR通路及T细胞耗竭特征。
  • MCL-PDLS重现体内依鲁替尼反应。
  • 依鲁替尼联合纳武利尤单抗可能对依鲁替尼耐药病例有效。

核心结论

  • MCL-PDLS重现MCL淋巴结特征及体内依鲁替尼反应,是研究MCL与免疫微环境相互作用及药物筛选的稳健工具,推动个体化治疗。

研究设计与样本

  • 研究构建首个人源MCL球状体(MCL-PDLS),由肿瘤B细胞、单核细胞和自体T细胞在多重系统中自组织形成盘状结构。

主要发现

  • MCL球状体中B细胞和T细胞保持活力并增殖,单核细胞分化为M2样巨噬细胞。
  • RNA-seq显示肿瘤细胞重现MCL淋巴结特征(增殖、NF-kB和BCR),T细胞呈现耗竭表型(PD1、TIM-3和TIGIT)。
  • MCL-PDLS重现体内依鲁替尼反应。
  • 依鲁替尼联合纳武利尤单抗可能通过增加干扰素γ和颗粒酶B释放对依鲁替尼耐药病例有效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mantle cell lymphoma (MCL), a rare and aggressive B-cell non-Hodgkin lymphoma, mainly develops in the lymph node (LN) and creates a protective and immunosuppressive niche that facilitates tumor survival, proliferation and chemoresistance. To capture disease heterogeneity and tumor microenvironment (TME) cues, we have developed the first patient-derived MCL spheroids (MCL-PDLS) that recapitulate tumor oncogenic pathways and immune microenvironment in a multiplexed system that allows easy drug screening, including immunotherapies. MCL spheroids, integrated by tumor B cells, monocytes and autologous T-cells self-organize in disc-shaped structures, where B and T-cells maintain viability and proliferate, and monocytes differentiate into M2-like macrophages. RNA-seq analysis demonstrated that tumor cells recapitulate hallmarks of MCL-LN (proliferation, NF-kB and BCR), with T cells exhibiting an exhaustion profile (PD1, TIM-3 and TIGIT). MCL-PDLS reproduces in vivo responses to ibrutinib and demonstrates that combination of ibrutinib with nivolumab (anti-PD1) may be effective in ibrutinib-resistant cases by engaging an immune response with increased interferon gamma and granzyme B release. In conclusion, MCL-PDLS recapitulates specific MCL-LN features and in vivo responses to ibrutinib, representing a robust tool to study MCL interaction with the immune TME and to perform drug screening in a patient-derived system, advancing toward personalized therapeutic approaches.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Araujo-Ayala F, Dobaño-López C, Valero JG, et al. A novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses. Leukemia. 2023. PMID: 37031299. doi:10.1038/s41375-023-01885-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。